United States · Bill · S
S. 2121 (119th)
SUPPORT for Patients and Communities Reauthorization Act of 2025
Introduced
18 June 2025
Last action
—
Status
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsors
—
Subjects
Discovery layer
Source updated
23 June 2026
Summary
SUPPORT for Patients and Communities Reauthorization Act of 2025 This bill reauthorizes and revises Department of Health and Human Services (HHS) programs that address substance use disorders, overdoses, and mental health. For example, the bill reauthorizes for FY2026-FY2030 grant and other programs relating to • addressing substance use disorders with respect to pregnant and postpartum women, • prevention and recovery from substance use disorders for youth, • housing for individuals in recovery from substance use disorders, • community organizations facilitating recovery from substance use disorders, • loan repayment for certain health care providers treating substance use disorders, • prevention of overdoses of controlled substances, • treatment of children experiencing psychological trauma, and • mental and behavioral health education and training for medical and allied health students. Also, the bill revises several programs, including by (1) expanding a program that supports resources for first responders to include the purchase of drugs or devices to treat non-opioid overdoses, (2) expanding a program that supports employment services for individuals in recovery so as to allow for the provision of related transportation services, and (3) temporarily authorizing a regional technical assistance center to assist the National Peer-Run Training and Technical Assistance Center for Addiction Recovery Support. Additionally, the bill establishes new requirements for HHS, including requirements relating to • protecting the National Suicide Prevention Lifeline program from cybersecurity threats, • establishing a Federal Interagency Work Group on Fentanyl Contamination of Illegal Drugs, and • reviewing and potentially revising the scheduling of approved products containing a combination of buprenorphine and naloxone under the Controlled Substances Act.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
2 official files
Introduced in Senate
Introduced in Senate
Introduced in Senate · EN · 18 June 2025
Introduced in Senate
summary · EN · 18 June 2025
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/119th-congress/senate-bill/2121
- Open data entity: https://api.congress.gov/v3/bill/119/s/2121